Scilex Holding Co (SCLXW) stock

SCLXWNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31Also trades as SCLX

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026Score 1/30

$0.04−0.00 (-1.53%)

Close on Oct 30, 2026Market cap $17.50MP/E –Yield –

Scilex price to sales ratio

The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.

Scilex's price to sales ratio was 0.6× on Oct 19, 2026, against 2.1× a year earlier. Over the last 5 years it ranged from 0.4× to 32.1×, with a median of 2.7×.

Price to Sales Ratio at the end of each year

Period	Period end	Value	Change (pts)
2026	Oct 19, 2026	0.6×	−1.2
2025	Dec 31, 2025	1.8×	+0.8
2024	Dec 31, 2024	1.0×	−3.2
2023	Dec 29, 2023	4.2×	−2.8
2022	Jan 31, 2022	7.0×	+0.0
2021	Dec 31, 2021	7.0×	–

Where these numbers come from

Parsed from the XBRL in Scilex's annual and quarterly filings with the SEC
Per-share figures adjusted for the 1-for-35 reverse split on Apr 15, 2025
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is SCLXW.

Compare: SCLXW vs PTHS · SCLXW vs TNXP · SCLXW vs LENZ · SCLXW vs CPIX · SCLXW vs CHRS

Revenue growth-28.5% · median 128.5%

Gross margin161.1% · median 78.6%

Operating margin-1136.4% · median -311.6%

Net margin-1469.8% · median -259.4%

Company	Revenue	Growth
CHRS	$50.94M	+61.0%
PTHS	$43.30M	–
SCLXW	$31.61M	-28.5%
CPIX	$31.27M	-1.1%
TNXP	$29.10M	+196.0%
LENZ	$21.48M	+329.5%

Company

Exchange: Nasdaq
Industry: Biological Products, (No Diagnostic Substances)
Fiscal year ends: December 31
Employees: 34
Auditor: BPM LLP
SEC CIK: 1820190

Advertisement
300 × 250